Developer docs
API playgroundTry for free, no card

Search company profiles

Adagene

Full company profile

uuid00005cg

Namestring
Adagene
Legal namestring
Adagene Inc.
Websiteurl
adagene.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Adagene Inc. is a clinical-stage immuno-oncology company developing proprietary antibody-based therapeutics using its Dynamic Precision Library (DPL) discovery platform, which combines computational biology and AI. The platform is organized around three technology pillars: NEObody, which targets unique epitopes with novel mechanisms of action; SAFEbody, which applies precision masking for tumor-microenvironment-localized activation to reduce on-target off-tumor toxicity; and POWERbody, which combines bispecific T-cell engager functionality with the same masking approach. Founded in November 2011 by Peter Luo, the company is headquartered in Suzhou, China with a regional presence in San Diego, and has been listed on Nasdaq under ticker ADAG since its February 2021 IPO.

The clinical pipeline is led by muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody in Phase 1b/2 development for microsatellite stable (MSS) colorectal cancer and hepatocellular carcinoma, supported by FDA Fast Track designation in MSS mCRC. Additional clinical-stage programs include ADG116 (NEObody CTLA-4 antagonist), ADG106 (CD137 agonist), ADG206 (POWERbody anti-CD137), and ADG104 (anti-PD-L1 in China trials), with preclinical assets ADG153, ADG138, and ADG152 extending the platform into masked CD47, HER2xCD3, and CD20xCD3 programs. Reported clinical signals include a 66.7% overall response rate for muzastotug combination therapy in HCC versus 32.5% for standard atezolizumab and bevacizumab, and a 31% confirmed ORR in late-line MSS colorectal cancer.

Adagene is pre-commercial and generates revenue primarily through upfront payments, milestone payments, and strategic investments from global pharmaceutical partners, including Merck (pembrolizumab combinations), Sanofi ($25M strategic investment July 2025 plus program options), Incyte (April 2026 clinical collaboration), Exelixis (SAFEbody ADC license), Third Arc Bio (CD3 T-cell engager license with up to $840M in potential milestones), and ADC Therapeutics. As of December 31, 2025, the company held $74.5 million in cash with FY2025 net loss of $17.6 million, and following the April 2026 $70 million public offering, expects cash runway into early 2028.

Short descriptiontext

Adagene is a clinical-stage immuno-oncology company developing proprietary antibody therapeutics using its AI-enabled Dynamic Precision Library platform across SAFEbody, NEObody, and POWERbody technologies. Its lead asset muzastotug targets CTLA-4 in MSS colorectal cancer and hepatocellular carcinoma under FDA Fast Track designation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, cancer immunotherapy, antibody discovery platform, oncology drug development, clinical-stage biopharmaceutical
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-stage antibody therapeutics for immuno-oncology
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Collaboration and Licensing Revenue
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotech company generating limited revenue from upfront payments, milestone payments, and research funding from strategic partnerships and licensing agreements with global pharmaceutical companies

biospace.com
2Strategic Investments
TypeSubscription Recurring
Description

Company raises capital through public offerings and strategic investments to fund clinical development operations

finance.yahoo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1NEObody
Description

Technology platform targeting unique epitopes with novel mechanism of action

adagene.com
+3 more records
Core offering1 text field

Adagene is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies for cancer treatment. Its core offering centers on its Dynamic Precision Library (DPL) discovery engine—a proprietary platform combining computational biology and AI—along with three enabling antibody technologies (NEObody, SAFEbody, POWERbody) and a pipeline of preclinical and clinical-stage drug candidates targeting solid tumors and hematologic malignancies. The company monetizes these assets through licensing deals, upfront and milestone payments, royalties, and clinical collaborations with global pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 66.7% overall response rate in hepatocellular carcinoma with muzastotug combination therapy vs 32.5% for standard atezolizumab and bevacizumab regimen
+2 more records
Product overview1 text field

Adagene is a clinical-stage oncology biotech company with a platform-driven approach to antibody discovery and development. The company's core offering consists of its Dynamic Precision Library (DPL) discovery platform, which encompasses three proprietary technology pillars: NEObody for novel epitope targeting, SAFEbody for precision masking and local activation, and POWERbody for empowered efficacy with tumor-selective activation. The company leverages computational biology and AI to drive its pipeline. The clinical portfolio includes lead program ADG126 (muzastotug), a masked anti-CTLA-4 SAFEbody in Phase 1b/2 for colorectal cancer and hepatocellular carcinoma; ADG116, a novel CTLA-4 NEObody; and ADG106, a CD137 agonist. Preclinical programs include ADG206 (POWERbody), ADG153 (anti-CD47 SAFEbody), ADG138 (HER2xCD3 POWERbody), and ADG152 (CD20xCD3 T-cell engager). The company has established global partnerships leveraging these technologies with Sanofi, Exelixis, Third Arc Bio, and clinical collaborations with Merck and Incyte.

Product and service1 record
1Dynamic Precision Library (DPL)
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

Clinical collaboration to evaluate combination therapy pairing Adagene's masked anti-CTLA-4 antibody muzastotug with Incyte's bispecific antibody INCA33890 targeting TGFβR2 and PD-1 for microsatellite stable colorectal cancer. Phase 1 trial expected to begin in 2026, sponsored by Incyte.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-02
Description

Multiple clinical trial collaborations evaluating Adagene's antibody candidates ADG116, ADG126, and ADG106 in combination with pembrolizumab (KEYTRUDA) across various solid tumors. Collaboration includes supply agreements and joint clinical development.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-13
Description

Licensing agreement where Third Arc Bio utilizes Adagene's SAFEbody technology to develop two masked CD3 T cell engagers for tumor antigens. Adagene receives $5 million upfront and potential milestone payments up to $840 million plus royalties. Adagene retains options for certain Asian markets.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-02-01
Description

Collaboration and license agreement where Exelixis utilizes Adagene's SAFEbody technology to develop masked antibody-drug conjugates. $11 million upfront payment to Adagene with potential for two targets. Adagene eligible for development and commercialization milestones plus royalties on net sales.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-10-26
Description

Clinical trial collaboration for Phase 1b/2 study of ADG106 in combination with nivolumab in patients with non-small cell lung cancer in Singapore.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-04-24
Description

License agreement for ADC Therapeutics to use Adagene's SAFEbody technology to generate masked antibodies combined with PBD cytotoxic payloads for novel ADC development against solid tumor target.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-01-07
Description

Collaboration with Dr. Richard Childs to discover antibodies targeting novel antigen expressed on tumor cells for CAR-T cell therapy development. Achieved milestone of discovering potentially first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2018-03-09
Description

Strategic development and manufacturing partnership supporting supply of Adagene's products for clinical trials under IND applications in both China and United States. Enables Adagene to focus on core competency in antibody discovery.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CytomX develops Probody therapeutics, the most direct platform-level comparable to Adagene's SAFEbody technology, using masked/conditionally activated antibodies designed to reduce on-target off-tumor toxicity. Both companies target similar oncology indications including CTLA-4 and pursue similar platform-partnering strategies with big pharma.

TypeBroad incumbent
Description

MacroGenics develops Fc-optimized and bispecific antibodies (DART platform) for immuno-oncology. Comparable to Adagene's NEObody/POWERbody approach for CTLA-4 and other immuno-oncology targets, MacroGenics is a broader incumbent in engineered antibody therapeutics development.

TypeBroad incumbent
Description

Zymeworks develops bispecific and multifunctional antibody therapeutics using its Azymetric and Effector Function platforms. Comparable to Adagene's POWERbody bispecific T-cell engager approach, Zymeworks represents a broader incumbent in engineered antibody platform development.

TypeDirect peer
Description

AbCellera operates an AI-powered antibody discovery platform that partners with pharmaceutical companies, paralleling Adagene's DPL platform model. Both companies use computational approaches to accelerate antibody discovery and pursue technology licensing and partnership business models.

TypeDirect peer
Description

BioAtla develops Conditionally Active Biologics (CAB) antibodies that are activated preferentially in tumor microenvironment, directly comparable to Adagene's SAFEbody tumor-localized activation approach. Both companies focus on masked antibody technology for immuno-oncology applications.

TypeEmerging player
Description

Schrödinger applies physics-based computational platform and AI to drug discovery across small molecules and biologics, with comparable AI-driven discovery philosophy to Adagene's DPL platform. While broader in modality, Schrödinger represents a peer in computational/AI-enabled therapeutic discovery.

TypeBroad incumbent
Description

Xencor develops the XmAb antibody engineering platform with bispecific and Fc-engineered antibodies. Notably, Adagene CEO Peter Luo was Xencor's first lead scientist in computational protein design, and Xencor represents an established platform-level peer in the broader antibody engineering space.

TypeDirect peer
Description

Compugen is a clinical-stage immuno-oncology company using computational biology and AI for antibody and target discovery, paralleling Adagene's AI-powered DPL approach. Both companies focus on novel immuno-oncology targets and use computational platforms for antibody engineering.

TypeDirect peer
Description

Shattuck Labs (which merged with Werewolf Therapeutics in 2025) develops masked cytokine and immune agonist platforms (PREDATOR/INDUKINE), using conditional activation approaches directly analogous to Adagene's SAFEbody and POWERbody technologies for tumor-selective immunotherapy.

TypeDirect peer
Description

Inhibrx develops multivalent and conditional biologics including masked antibody approaches for oncology. The company's sdAb-based platform for tumor-selective activation parallels Adagene's SAFEbody strategy of engineering conditional activity into antibody therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adagene

Clinical-stage antibody therapeutics for immuno-oncologyadagene.com

Adagene is a clinical-stage immuno-oncology company developing proprietary antibody therapeutics using its AI-enabled Dynamic Precision Library platform across SAFEbody, NEObody, and POWERbody technologies. Its lead asset muzastotug targets CTLA-4 in MSS colorectal cancer and hepatocellular carcinoma under FDA Fast Track designation.

What Adagene does

Adagene Inc. is a clinical-stage immuno-oncology company developing proprietary antibody-based therapeutics using its Dynamic Precision Library (DPL) discovery platform, which combines computational biology and AI. The platform is organized around three technology pillars: NEObody, which targets unique epitopes with novel mechanisms of action; SAFEbody, which applies precision masking for tumor-microenvironment-localized activation to reduce on-target off-tumor toxicity; and POWERbody, which combines bispecific T-cell engager functionality with the same masking approach. Founded in November 2011 by Peter Luo, the company is headquartered in Suzhou, China with a regional presence in San Diego, and has been listed on Nasdaq under ticker ADAG since its February 2021 IPO.

The clinical pipeline is led by muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody in Phase 1b/2 development for microsatellite stable (MSS) colorectal cancer and hepatocellular carcinoma, supported by FDA Fast Track designation in MSS mCRC. Additional clinical-stage programs include ADG116 (NEObody CTLA-4 antagonist), ADG106 (CD137 agonist), ADG206 (POWERbody anti-CD137), and ADG104 (anti-PD-L1 in China trials), with preclinical assets ADG153, ADG138, and ADG152 extending the platform into masked CD47, HER2xCD3, and CD20xCD3 programs. Reported clinical signals include a 66.7% overall response rate for muzastotug combination therapy in HCC versus 32.5% for standard atezolizumab and bevacizumab, and a 31% confirmed ORR in late-line MSS colorectal cancer.

Adagene is pre-commercial and generates revenue primarily through upfront payments, milestone payments, and strategic investments from global pharmaceutical partners, including Merck (pembrolizumab combinations), Sanofi ($25M strategic investment July 2025 plus program options), Incyte (April 2026 clinical collaboration), Exelixis (SAFEbody ADC license), Third Arc Bio (CD3 T-cell engager license with up to $840M in potential milestones), and ADC Therapeutics. As of December 31, 2025, the company held $74.5 million in cash with FY2025 net loss of $17.6 million, and following the April 2026 $70 million public offering, expects cash runway into early 2028.

Adagene firmographics

Firmographics
Name
Adagene
Legal name
Adagene Inc.
Website
https://adagene.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Adagene is a clinical-stage immuno-oncology company developing proprietary antibody therapeutics using its AI-enabled Dynamic Precision Library platform across SAFEbody, NEObody, and POWERbody technologies. Its lead asset muzastotug targets CTLA-4 in MSS colorectal cancer and hepatocellular carcinoma under FDA Fast Track designation.
Ownership category
akta.pro rank

Adagene industry classification

Industry
Product category
Clinical-stage antibody therapeutics for immuno-oncology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody therapeutics
  • Cancer immunotherapy
  • Antibody discovery platform
  • Oncology drug development
  • Clinical-stage biopharmaceutical

Where Adagene is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Adagene business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Collaboration and Licensing Revenue: Pre-revenue clinical-stage biotech company generating limited revenue from upfront payments, milestone payments, and research funding from strategic partnerships and licensing agreements with global pharmaceutical companies
  2. Strategic Investments: Company raises capital through public offerings and strategic investments to fund clinical development operations

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Adagene product offering

Product offering

Core offering

Adagene is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies for cancer treatment. Its core offering centers on its Dynamic Precision Library (DPL) discovery engine—a proprietary platform combining computational biology and AI—along with three enabling antibody technologies (NEObody, SAFEbody, POWERbody) and a pipeline of preclinical and clinical-stage drug candidates targeting solid tumors and hematologic malignancies. The company monetizes these assets through licensing deals, upfront and milestone payments, royalties, and clinical collaborations with global pharmaceutical companies.

Product overview

Adagene is a clinical-stage oncology biotech company with a platform-driven approach to antibody discovery and development. The company's core offering consists of its Dynamic Precision Library (DPL) discovery platform, which encompasses three proprietary technology pillars: NEObody for novel epitope targeting, SAFEbody for precision masking and local activation, and POWERbody for empowered efficacy with tumor-selective activation. The company leverages computational biology and AI to drive its pipeline. The clinical portfolio includes lead program ADG126 (muzastotug), a masked anti-CTLA-4 SAFEbody in Phase 1b/2 for colorectal cancer and hepatocellular carcinoma; ADG116, a novel CTLA-4 NEObody; and ADG106, a CD137 agonist. Preclinical programs include ADG206 (POWERbody), ADG153 (anti-CD47 SAFEbody), ADG138 (HER2xCD3 POWERbody), and ADG152 (CD20xCD3 T-cell engager). The company has established global partnerships leveraging these technologies with Sanofi, Exelixis, Third Arc Bio, and clinical collaborations with Merck and Incyte.

Differentiator

Problem solved

Functional benefit

Brands

  • NEObody: Technology platform targeting unique epitopes with novel mechanism of action
  • SAFEbody
  • POWERbody
  • Dynamic Precision Library

Products and services

  • Dynamic Precision Library (DPL)

Quantifiable outcome

  • 66.7% overall response rate in hepatocellular carcinoma with muzastotug combination therapy vs 32.5% for standard atezolizumab and bevacizumab regimen
  • +2 more outcomes

Companies that use Adagene

Customer profile

Segments1 record

Ideal customer profiles2 records

Adagene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Adagene partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, major and minor.

  • IncytecoreStrategic or Co-development Partner · 2 April 2026Clinical collaboration to evaluate combination therapy pairing Adagene's masked anti-CTLA-4 antibody muzastotug with Incyte's bispecific antibody INCA33890 targeting TGFβR2 and PD-1 for microsatellite stable colorectal cancer. Phase 1 trial expected to begin in 2026, sponsored by Incyte.
  • Merck (MSD)coreStrategic or Co-development Partner · 2 April 2026Multiple clinical trial collaborations evaluating Adagene's antibody candidates ADG116, ADG126, and ADG106 in combination with pembrolizumab (KEYTRUDA) across various solid tumors. Collaboration includes supply agreements and joint clinical development.
  • Third Arc BiocoreOEM/ Whitelabel/ Licensing Partner · 13 November 2025Licensing agreement where Third Arc Bio utilizes Adagene's SAFEbody technology to develop two masked CD3 T cell engagers for tumor antigens. Adagene receives $5 million upfront and potential milestone payments up to $840 million plus royalties. Adagene retains options for certain Asian markets.
  • ExelixismajorOEM/ Whitelabel/ Licensing Partner · 1 February 2021Collaboration and license agreement where Exelixis utilizes Adagene's SAFEbody technology to develop masked antibody-drug conjugates. $11 million upfront payment to Adagene with potential for two targets. Adagene eligible for development and commercialization milestones plus royalties on net sales.
  • National Cancer Centre Singapore / National University Cancer Institute SingaporeminorStrategic or Co-development Partner · 26 October 2019Clinical trial collaboration for Phase 1b/2 study of ADG106 in combination with nivolumab in patients with non-small cell lung cancer in Singapore.
  • ADC TherapeuticsmajorOEM/ Whitelabel/ Licensing Partner · 24 April 2019License agreement for ADC Therapeutics to use Adagene's SAFEbody technology to generate masked antibodies combined with PBD cytotoxic payloads for novel ADC development against solid tumor target.
  • National Heart, Lung, and Blood Institute (NIH)majorStrategic or Co-development Partner · 7 January 2019Collaboration with Dr. Richard Childs to discover antibodies targeting novel antigen expressed on tumor cells for CAR-T cell therapy development. Achieved milestone of discovering potentially first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma.
  • WuXi BiologicscoreImplementation/ SI/ Consulting Partner · 9 March 2018Strategic development and manufacturing partnership supporting supply of Adagene's products for clinical trials under IND applications in both China and United States. Enables Adagene to focus on core competency in antibody discovery.

Scale indicators6 records

Recent moves9 records

Expansion highlights7 records

Adagene competitors and assessment

Company assessment

Direct peers

  • CytomX Therapeutics: CytomX develops Probody therapeutics, the most direct platform-level comparable to Adagene's SAFEbody technology, using masked/conditionally activated antibodies designed to reduce on-target off-tumor toxicity. Both companies target similar oncology indications including CTLA-4 and pursue similar platform-partnering strategies with big pharma.
  • AbCellera: AbCellera operates an AI-powered antibody discovery platform that partners with pharmaceutical companies, paralleling Adagene's DPL platform model. Both companies use computational approaches to accelerate antibody discovery and pursue technology licensing and partnership business models.
  • BioAtla: BioAtla develops Conditionally Active Biologics (CAB) antibodies that are activated preferentially in tumor microenvironment, directly comparable to Adagene's SAFEbody tumor-localized activation approach. Both companies focus on masked antibody technology for immuno-oncology applications.
  • Compugen: Compugen is a clinical-stage immuno-oncology company using computational biology and AI for antibody and target discovery, paralleling Adagene's AI-powered DPL approach. Both companies focus on novel immuno-oncology targets and use computational platforms for antibody engineering.
  • Shattuck Labs: Shattuck Labs (which merged with Werewolf Therapeutics in 2025) develops masked cytokine and immune agonist platforms (PREDATOR/INDUKINE), using conditional activation approaches directly analogous to Adagene's SAFEbody and POWERbody technologies for tumor-selective immunotherapy.
  • Inhibrx Biosciences: Inhibrx develops multivalent and conditional biologics including masked antibody approaches for oncology. The company's sdAb-based platform for tumor-selective activation parallels Adagene's SAFEbody strategy of engineering conditional activity into antibody therapeutics.

Broad incumbents

  • MacroGenics: MacroGenics develops Fc-optimized and bispecific antibodies (DART platform) for immuno-oncology. Comparable to Adagene's NEObody/POWERbody approach for CTLA-4 and other immuno-oncology targets, MacroGenics is a broader incumbent in engineered antibody therapeutics development.
  • Zymeworks: Zymeworks develops bispecific and multifunctional antibody therapeutics using its Azymetric and Effector Function platforms. Comparable to Adagene's POWERbody bispecific T-cell engager approach, Zymeworks represents a broader incumbent in engineered antibody platform development.
  • Xencor: Xencor develops the XmAb antibody engineering platform with bispecific and Fc-engineered antibodies. Notably, Adagene CEO Peter Luo was Xencor's first lead scientist in computational protein design, and Xencor represents an established platform-level peer in the broader antibody engineering space.

Emerging players

  • Schrödinger: Schrödinger applies physics-based computational platform and AI to drug discovery across small molecules and biologics, with comparable AI-driven discovery philosophy to Adagene's DPL platform. While broader in modality, Schrödinger represents a peer in computational/AI-enabled therapeutic discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Adagene social profiles

Digital presence

Adagene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adagene leadership team

Management profile

Number of profiles

Profiles13 records

Adagene funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adagene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adagene

What does Adagene do?

Adagene is a clinical-stage biopharmaceutical company that develops antibody-based immunotherapies for cancer treatment. Its core offering centers on its Dynamic Precision Library (DPL) discovery engine—a proprietary platform combining computational biology and AI—along with three enabling antibody technologies (NEObody, SAFEbody, POWERbody) and a pipeline of preclinical and clinical-stage drug candidates targeting solid tumors and hematologic malignancies. The company monetizes these assets through licensing deals, upfront and milestone payments, royalties, and clinical collaborations with global pharmaceutical companies.

Is Adagene a public or private company?

Adagene is a public company. It is classified as public and is currently operating.

When was Adagene founded?

Adagene was founded in 2011. It employs 51 to 100 people.

Where is Adagene based?

Adagene is headquartered in Suzhou, China, in the Asia region.

How does Adagene make money?

Two revenue lines are on record. Collaboration and Licensing Revenue is the primary driver. The others are strategic Investments.

Who are Adagene's main competitors?

Direct peers on record are CytomX Therapeutics, AbCellera, BioAtla, Compugen, Shattuck Labs and Inhibrx Biosciences. Broad incumbents are MacroGenics, Zymeworks and Xencor. Schrödinger is listed as an emerging player.

Does Adagene have an API?

No public API is recorded for Adagene.

What industry is Adagene in?

Adagene's product category is Clinical-stage antibody therapeutics for immuno-oncology. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScienmagCity of Hope, Adagene Launch Trial Testing Combination Immunotherapy forCity of Hope and Adagene launched a Phase 1 trial testing the combination of ivonescimab and muzastotug (ADG126) in patients with metastatic colorectal cancer who have progressed on prior therapy. The trial enrolls up to 36 patients to evaluate safety and preliminary antitumor activity, with plans to integrate chemotherapy in later stages.TradingViewAdagene Inc. (ADAG) Opens Phase 1 Trial of ADG126 Combination in Colorectal CancerAdagene and City of Hope launched a Phase 1 trial of ivonescimab and ADG126 in advanced microsatellite stable colorectal cancer, enrolling up to 36 patients. The study will assess safety and efficacy to determine an optimal dose before planned exploration with chemotherapy.TradingViewAdagene Inc. (ADAG) Opens Phase 1 Cancer Combination TrialAdagene and City of Hope launched a Phase 1 trial of muzastotug and ivonescimab for advanced microsatellite stable colorectal cancer, enrolling up to 36 patients. The trial provides no prior-period comparison, and initial patients had progressed on prior systemic therapy. Safety and preliminary antitumor activity will determine whether the program advances.Business & FinancialAdagene Announces Completion Of Enrollment In Randomized Dose Optimization Phase 2 Trial Of Muzastotug In Combination With KEYTRUDA® (Pembrolizumab) In Microsatellite Stable Colorectal CancerAdagene completed enrollment in its randomized Phase 2 dose-optimization trial of muzastotug with KEYTRUDA in late-line microsatellite stable colorectal cancer. The trial enrolled 60 patients, and initial results are expected in the first half of 2027.Stock TitanAdagene completes enrollment in 60-patient Phase 2 trialAdagene completed enrollment of 60 patients in its randomized Phase 2 trial of muzastotug plus KEYTRUDA in microsatellite stable colorectal cancer. Initial results are expected in the first half of 2027 to inform the Phase 3 dose regimen. The company retains worldwide commercial rights to muzastotug.American Banking and Market NewsAdagene Inc. Sponsored ADR (NASDAQ:ADAG) Stock Has Average Price Target of $8.25Adagene Inc. shares received an average "Moderate Buy" rating from five analysts, with an average price target of $8.25. CEO Peter Luo bought 20,290 shares at $3.15, increasing his stake by 29.73%, while Renaissance Technologies acquired a new position. The stock opened at $2.29, down 8.8%.American Banking and Market NewsAdagene (NASDAQ:ADAG) Stock Rating Reaffirmed as Buy by Chardan CapitalChardan Capital reiterated a buy rating on Adagene with a $9.00 price target, implying 235.82% upside from the previous close. The consensus rating is Moderate Buy with a $8.25 target. CEO Peter Luo bought 20,290 shares at $3.15, increasing his stake by 29.73%.MarketScreenerAdagene Inc. Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte?S Inca33890 in Patients with Microsatellite Stable Colorectal CancerAdagene Inc. announced the first patient dosing in a Phase 1 study of muzastotug combined with Incyte's INCA33890 in microsatellite stable colorectal cancer. The open-label trial targets third-line patients with and without liver metastases, assessing safety and efficacy. The combination aims to broaden clinical benefit via complementary mechanisms.MarketBeatAdagene (NASDAQ:ADAG) Stock Keeps "Buy" Rating at Chardan CapitalChardan Capital reaffirmed a buy rating on Adagene with a $9.00 price target, implying 248.84% upside from the previous close. The stock opened at $2.58, and CEO Peter Luo acquired 22,966 shares at $3.65 each. Analysts average a Moderate Buy rating with a $8.25 target.